Composition for promoting child development

A children's nutritional composition with NMN as an NAD precursor addresses the challenges of improving athletic performance, reducing triglycerides, and suppressing fat accumulation, enhancing child development by leveraging NMN's benefits in breast milk, resulting in improved motor skills and metabolic health.

WO2024237195A1PCT designated stage expired Publication Date: 2024-11-21MEIJI HOLDINGS
View PDF 20 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/017394
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2024-05-10
Publication Date
2024-11-21

AI Technical Summary

Technical Problem

Current compositions fail to effectively promote child development, particularly in improving athletic performance, reducing blood triglyceride levels, and suppressing fat accumulation in children, while existing technologies have shown promise with NAD+ precursors like NMN but lack clear application in pediatric nutrition.

Method used

A nutritional composition for children containing nicotinamide adenine dinucleotide (NAD) precursors, specifically nicotinamide mononucleotide (NMN), is administered to improve motor skills, reduce blood triglycerides, and inhibit fat accumulation, leveraging its presence in breast milk and proven benefits in animal models.

Benefits of technology

The composition enhances grip strength, locomotor activity, reduces blood triglycerides and sugar levels, and suppresses fat accumulation, contributing to healthy growth and development in children, with NMN's presence in breast milk ensuring safety and efficacy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024017394_21112024_PF_FP_ABST
    Figure JP2024017394_21112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention addresses the problem of making clear the physiological significance and function, such as an effect on child growth, of nicotinamide mononucleotide (NMN) that is contained in breast milk. Provided is a composition which includes a precursor of NAD and which is for improving athletic ability of a child. The improvement in athletic ability is preferably any one selected from the group consisting of the promotion of the development of skeletal muscles and improvement in activity. Also provided is a composition which includes a precursor of NAD and which is for reducing a blood triglyceride level of a child. Also provided is a composition which includes a precursor of NAD and which is for reducing a blood sugar level of a child. Also provided is a composition which includes a precursor of NAD and which is for suppressing an accumulation of fat in a child.
Need to check novelty before this filing date? Find Prior Art

Description

Compositions for promoting child development

[0001] The present invention relates to a composition for improving athletic performance in children, a composition for reducing blood triglyceride levels in children, a composition for reducing blood glucose levels in children, and a composition for inhibiting fat accumulation in children. The present invention is useful in the fields of development, health, and nutrition of children, particularly infants and young children, and in the fields of producing foods and beverages therefor.

[0002] β-Nicotinamide Mononucleotide (NMN) is a precursor of Nicotinamide Adenine Dinucleotide (NAD), which is necessary for humans to maintain vital functions, and is a compound belonging to vitamin B3. NAD has been reported to have beneficial effects, mainly in relation to aging.

[0003] Regarding athletic ability, for example, it has been reported that elderly mice overexpressing SIRT1, which plays an important role in regulating metabolic reactions in various tissues through NAD-dependent enzyme activity, showed improved skeletal muscle function and increased spontaneous activity (Non-Patent Document 1). Additionally, it has been reported that elderly men who received 250 mg of NMN per day for 6 or 12 weeks showed significant improvements in walking speed and left grip strength (Non-Patent Document 2). Patent Document 1 describes a composition for preventing chemotherapy-induced neurotoxic damage in a subject, the composition comprising a compound that increases NAD+ levels in the subject, the chemotherapy-induced neurotoxic damage including chemotherapy-induced cognitive impairment (CICI), the subject being i) a subject who has been exposed to a chemotherapeutic agent and in whom CICI has not yet been induced, or ii) a subject who is currently being exposed to a chemotherapeutic agent, or iii) a subject who is scheduled to be exposed to a chemotherapeutic agent, the compound that increases NAD+ levels being an NAD+ precursor selected from nicotinamide mononucleotide (NMN), nicotinic acid, nicotinamide, nicotinamide riboside (NR), nicotinic acid mononucleotide, nicotinic acid riboside, or a salt thereof. In another aspect, Patent Document 1 describes a method for improving neurological function and motor skills in a subject, the method comprising administering to the subject an effective amount of an agent that increases NAD+ levels in the subject.Patent Literature 2 describes a composition for imparting health benefits to a female mammal and / or her offspring, comprising a specific nicotinamide adenine dinucleotide (NAD) precursor, wherein the composition is administered orally, transmucosally (e.g., intranasally), by inhalation, by injection, or topically (e.g., transdermally) to the female mammal, and the offspring orally ingests breast milk from the female mammal, thereby imparting the health benefits to the offspring, wherein the health benefits imparted to the female mammal include reduced weight gain associated with pregnancy, promoted weight loss after pregnancy, and / or increased breast milk production during lactation, and the health benefits imparted to the offspring include increased brain mass, improved physical performance, prevention of age-related weight gain, and / or reduced anxiety. Patent Literature 3 describes a method for increasing the athletic performance of a subject, comprising the step of administering an effective amount of an NAD precursor to the subject.

[0004] Regarding triglycerides, for example, a study in which mice were fed a high-fat diet and then administered NMN reported improved lipid metabolism and reduced liver triglyceride levels (Non-Patent Document 3). Patent Document 4 describes a study in which three subjects (in their 50s) with elevated blood triglyceride levels were administered two hard capsules containing 20 mg of resveratrol and 20 mg of β-nicotinamide mononucleotide, and two hard capsules containing 20 mg of resveratrol, 20 mg of β-nicotinamide mononucleotide, and 120 mg of niacinamide, once daily for four consecutive weeks (28 days), resulting in a reduction in triglyceride levels. Patent Document 5 describes an adiponectin secretion enhancer characterized by containing β-nicotinamide mononucleotide or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient, and states that promoting adiponectin secretion enables the treatment and prevention of obesity-related systemic metabolic disorders, particularly multi-organ insulin resistance. Patent Document 6 describes a method for treating or preventing at least one physical condition selected from the group consisting of oxidative stress, conditions associated with oxidative stress, decreased glutathione levels, and conditions associated with decreased glutathione levels, the method comprising administering an effective amount of a combination of a nicotinamide adenine dinucleotide (NAD+) precursor and at least one ketone or ketone precursor to an individual in need of the combination, and cites elevated triglyceride levels as an example of the physical condition.

[0005] Furthermore, with regard to blood glucose levels, for example, it has been reported that administration of NMN improved impaired glucose tolerance in mice caused by long-term maternal and post-weaning feeding of a high-fat diet (Non-Patent Document 3, cited above). Administration of NMN restored intestinal NAD+ levels in model mice with reduced glucagon-like peptide-1 (GLP-1) production and diet-induced obese mice, and also reversed obesity-related metabolic disorders indicated by reduced ileal proglucagon expression and GLP-1 production, as well as postprandial hyperglycemia (Non-Patent Document 4). Patent Document 7 describes an agent for enhancing glucose uptake in muscle tissue, containing a β-NMN-containing yeast extract as an active ingredient. Patent Document 8 also describes a pharmaceutical or health food composition, preferably containing nicotinamide mononucleotide and mogroside, and states that this composition is intended to lower blood glucose levels, promote the growth and repair of pancreatic islet cells, and combat hyperglycemia and / or diabetes.

[0006] Furthermore, with regard to the suppression of fat accumulation, it has been reported that, for example, impaired glucose tolerance caused by long-term feeding of a high-fat diet in mice during maternal and post-weaning periods was improved by administration of NMN (Non-Patent Document 3 cited above), and similarly, administration of NMN to mice fed a high-fat diet improved obesity-related metabolic disorders indicated by impaired lipid metabolism and glucose tolerance (Non-Patent Document 4 cited above).

[0007] The aforementioned Patent Document 7 describes an agent for enhancing glucose uptake in muscle tissue, which contains a β-NMN-containing yeast extract as an active ingredient, and states that this agent can be used as an agent for preventing or ameliorating diabetes and various complications caused by diabetes, such as obesity. Furthermore, the aforementioned Patent Document 8 describes a pharmaceutical composition or health food composition, preferably containing nicotinamide mononucleotide and a mogroside, and states that this composition can be used to control fat accumulation and body weight.

[0008] On the other hand, it has been reported that NMN synthesis is specifically enhanced in rat mammary glands during lactation (Non-Patent Document 5). Furthermore, it has recently been revealed that human breast milk contains NAD+ metabolites, including nicotinamide, and that NMN is particularly abundant among them (Non-Patent Document 6). Furthermore, using an animal model, it has been reported that lactating male mice were orally administered nicotinamide riboside (NR) daily from day 2 to day 20 of age, weaned on day 21, and fed a high-fat diet for 10 weeks from day 90. Compared to the control group, the NR-treated mice showed beneficial effects on lipid and energy metabolism in skeletal muscle and liver in adulthood (Non-Patent Document 7).

[0009] International Publication WO2016 / 176437 (Patent No. 2018-514548, Patent No. 7193232) International Publication WO2018 / 102426 (Patent No. 2020-504168, Patent No. 7136795) International Publication WO2018 / 112541 (Patent No. 2020-504722) International Publication WO2016 / 158212 (Patent No. 6545256) JP 2018-131418 A International Publication WO2019 / 242982 (Patent No. 2021-528372) JP 2018-203691 A (Patent No. 7093161) International Publication WO2020 / 177153 (Patent No. 2022-534165)

[0010] Satoh A et al, Cell Metab. 2013 Sep 3;18(3):416-30.Igarashi M et al, NPJ Aging. 2022 May 1;8(1):5.Uddin GM et al, Cells. 2020 Mar 25;9(4):791.Nagahisa T et al,Endocrinology. 2022 Apr 1;163(4):bqac023.AL Greenbaum et al, Biochem J 1 March 1968; 107 (1): 55-62.J Chromato B 2019; 1110-1111: 74-80Alba Serrano et ai, Nutrients 2022, 14, 2259.

[0011] Breast milk contains NMN, but the physiological significance and function of NMN, such as its effect on child development, remain unclear.

[0012] The present invention provides the following: [1] A nutritional composition for children, comprising a precursor of nicotinamide adenine dinucleotide (NAD), for promoting child development in any one of the areas selected from improving athletic ability, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation. [2] The composition according to [1], which is a composition for improving athletic ability, wherein the improvement in athletic ability is any one selected from the group consisting of promoting skeletal muscle development and improving activity. [3] The composition according to [1] or [2], which is a composition for improving athletic ability, wherein the improvement in athletic ability is measured by any one selected from the group consisting of improving muscle strength, increasing spontaneous activity, and increasing movement speed. [4] The composition according to any one of [1] to [3], wherein the promotion of child development is promoting the development of children after the weaning period. [5] The composition according to any one of [1] to [4], wherein the promotion of child development is promoting the development of children after the age of three. [6] The composition according to any one of [1] to [5], which is intended for consumption by infants or toddlers. [7] The composition described in any one of 1 to 5, for ingestion by pre-weaning children. [8] The composition described in any one of 1 to 7, in a form selected from the group consisting of infant formula, infant liquid formula, and breast milk substitute. [9] The composition described in any one of 1 to 8, in which the NAD precursor is nicotinamide mononucleotide (NMN).

[10] The composition described in any one of 1 to 9, in which the NMN concentration upon ingestion is 0.05 μg / mL or more.

[11] The composition described in any one of 1 to 10, in the form of infant formula, containing 0.1 mg or more of NMN per 100 g.

[12] A composition containing a nicotinamide adenine dinucleotide (NAD) precursor, for ingestion by pre-weaning children to promote post-weaning child development.

[13] The composition described in 12, in which the promotion of child development is selected from the group consisting of improved motor skills, reduced blood triglycerides, reduced blood glucose levels, and suppressed fat accumulation.

[0013] The present invention provides the following:

[101] A nutritional composition for children comprising a precursor of nicotinamide adenine dinucleotide (NAD) for use in a method for promoting child development in any area selected from improving athletic performance, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation. Use of a precursor of nicotinamide adenine dinucleotide (NAD) in the manufacture of a nutritional composition for children for promoting child development in any area selected from improving athletic performance, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation. A method or non-therapeutic method for promoting child development in any area selected from improving athletic performance, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation, comprising the step of administering to a subject a nutritional composition for children comprising a precursor of nicotinamide adenine dinucleotide (NAD).

[102] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use of a nutritional composition for children containing a precursor of nicotinamide adenine dinucleotide (NAD) for promoting child development in any one of a subject selected from improving motor ability, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation.

[103] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use of the composition according to claim 101 for improving motor ability, wherein the improvement in motor ability is any one selected from the group consisting of promoting skeletal muscle development and increasing activity.

[104] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use of the composition according to any one of claims 101 to 103 for improving motor ability, wherein the improvement in motor ability is measured by any one selected from the group consisting of increased muscle strength, increased spontaneous activity, and increased movement speed.

[104] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use of the composition according to any one of claims 101 to 103, wherein the promotion of child development is promoting the development of children after weaning.

[105] The composition, use in manufacture, method or non-therapeutic method, use or non-therapeutic use according to any one of claims 101 to 104, wherein promoting child development is promoting child development after the age of 3.

[106] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to any one of items 101 to 105, wherein the composition is intended for consumption by infants or young children.

[107] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to any one of items 101 to 105, wherein the composition is intended for consumption by children before weaning.

[108] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to any one of items 101 to 107, wherein the composition is in a form selected from the group consisting of infant formula, infant formula, and breast milk substitute.

[109] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to any one of items 101 to 108, wherein the precursor of NAD is nicotinamide mononucleotide (NMN).

[110] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to any one of items 101 to 109, wherein the composition has an NMN concentration of 0.05 μg / mL or more upon ingestion.

[111] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to any one of items 101 to 110, wherein the composition is in the form of infant formula and contains 0.1 mg or more of NMN per 100 g.

[112] A nicotinamide adenine dinucleotide (NAD) precursor or a composition comprising the same, for use in a method for administering to pre-weaning children to promote post-weaning development. Use of a nicotinamide adenine dinucleotide (NAD) precursor in the manufacture of a composition for use in a method for administering to pre-weaning children to promote post-weaning development. A method or non-therapeutic method for enhancing post-weaning development in a pre-weaning child, comprising administering to a subject a precursor of nicotinamide adenine dinucleotide (NAD).A use or non-therapeutic use of a precursor of nicotinamide adenine dinucleotide (NAD) for enhancing post-weaning development in a pre-weaning child.

[113] The composition, use in manufacturing, method or non-therapeutic method, use or non-therapeutic use according to 112, wherein the promotion of child development is any one selected from improved motor skills, reduced blood triglycerides, reduced blood glucose levels, and suppressed fat accumulation.

[0014] The present invention provides the following:

[201] A composition for improving the motor skills of children, comprising a precursor of nicotinamide adenine dinucleotide (NAD).

[202] The composition according to 201, wherein the improvement in motor skills is any one selected from the group consisting of promoting skeletal muscle development and improving activity.

[203] The composition according to 201 or 202, wherein the improvement in motor skills is measured by any one selected from the group consisting of improving muscle strength, increasing spontaneous activity, and increasing movement speed.

[204] The composition according to any one of 201 to 203, wherein the improvement in motor skills of children is an improvement in the motor skills of infants or toddlers.

[205] The composition according to any one of 201 to 204, wherein the improvement in motor skills of children is an improvement in the motor skills of children after weaning.

[206] The composition according to any one of 201 to 205, for administration to infants or toddlers.

[207] The composition according to any one of 201 to 205, for administration to children before weaning.

[208] The composition according to any one of items 201 to 207, which is in a form selected from the group consisting of infant formula, infant liquid formula, and breast milk substitute.

[209] The composition according to any one of items 201 to 208, wherein the NAD precursor is nicotinamide mononucleotide (NMN).

[210] The composition according to item 209, wherein the concentration of NMN upon ingestion is 0.05 μg / mL or more.

[211] The composition according to item 209 or 210, which is in the form of infant formula and contains 0.1 mg or more of NMN per 100 g.

[0015] The present invention also provides the following:

[301] A composition for reducing blood triglyceride levels in children, comprising a precursor of nicotinamide adenine dinucleotide (NAD).

[302] The composition according to 301, wherein the reduction in blood triglyceride levels in children is a reduction in blood triglyceride levels in infants or young children.

[303] The composition according to 301 or 302, wherein the reduction in blood triglyceride levels in children is a reduction in blood triglyceride levels in children after weaning.

[304] The composition according to any one of 301 to 303, for consumption by infants or young children.

[305] The composition according to any one of 301 to 303, for consumption by children before weaning.

[306] The composition according to any one of 301 to 305, in any form selected from the group consisting of infant formula, liquid infant formula, and breast milk substitute.

[307] The composition according to any one of items 301 to 306, wherein the precursor of NAD is nicotinamide mononucleotide (NMN).

[308] The composition according to item 307, wherein the concentration of NMN upon ingestion is 0.05 μg / ml or more.

[309] The composition according to items 307 or 308, which is in the form of infant formula and contains 0.1 mg or more of NMN per 100 g.

[0016] The present invention also provides the following:

[401] A composition for reducing blood glucose levels in children, comprising a precursor of nicotinamide adenine dinucleotide (NAD).

[402] The composition according to 401, wherein the reduction in blood glucose levels in children is a reduction in blood glucose levels in infants or toddlers.

[403] The composition according to 401 or 402, wherein the reduction in blood glucose levels in children is a reduction in blood glucose levels in children after weaning.

[404] The composition according to any one of 401 to 403, for consumption by infants or toddlers.

[405] The composition according to any one of 401 to 403, for consumption by children before weaning.

[406] The composition according to any one of 401 to 405, in any form selected from the group consisting of infant formula, liquid infant formula, and breast milk substitute.

[407] The composition according to any one of 401 to 406, wherein the precursor of NAD is nicotinamide mononucleotide (NMN).

[408] The composition according to 407, wherein the concentration of NMN upon ingestion is 0.05 μg / ml or more.

[409] The composition according to 407 or 408, which is in the form of infant formula and contains 0.1 mg or more of NMN per 100 g.

[0017] The present invention also provides the following:

[501] A composition for suppressing adiposity in children, comprising a precursor of nicotinamide adenine dinucleotide (NAD).

[502] The composition according to 501, wherein the suppression of adiposity in children is suppression of adiposity in infants or young children.

[503] The composition according to 501 or 502, wherein the suppression of adiposity in children is suppression of adiposity in children after weaning.

[504] The composition according to any one of 501 to 503, for administration to infants or young children.

[505] The composition according to any one of 501 to 503, for administration to children before weaning.

[506] The composition according to any one of 501 to 505, in any form selected from the group consisting of infant formula, liquid infant formula, and breast milk substitute.

[507] The composition according to any one of 501 to 506, wherein the precursor of NAD is nicotinamide mononucleotide (NMN).

[508] The composition according to 507, wherein the concentration of NMN upon ingestion is 0.05 μg / ml or more.

[509] The composition according to 507 or 508, which is in the form of infant formula and contains 0.1 mg or more of NMN per 100 g.

[0018] The composition of the present invention can contribute to children's future healthy growth by improving their athletic ability, reducing their blood triglyceride levels, reducing their blood glucose levels, and suppressing their fat accumulation. NMN, one of the active ingredients, is naturally contained in breast milk, so it can safely exert its intended effects in children. The present invention provides information on the relationship between NMN ingested before weaning and athletic ability, blood triglyceride levels, blood glucose levels, and fat accumulation.

[0019] The composition of one embodiment is expected to be applicable to the treatment of diseases or conditions related to athletic performance in children. The composition of one embodiment is expected to be applicable to the treatment of diseases or conditions related to blood triglyceride levels in children. The composition of one embodiment is expected to be applicable to the treatment of diseases or conditions related to blood glucose levels in children. The composition of one embodiment is expected to be applicable to the treatment of diseases or conditions related to fat accumulation in children.

[0020] Furthermore, the composition of the present invention is expected to be useful in improving the nutritional status of children and maintaining and promoting their health.

[0021] Grip strength. Grip strength was measured 3 weeks after weaning. Ctrl: control group, NMN:NMN group, n=20 for each group, values ​​are mean ± standard error, *: p<0.05 Student's t-test vs Ctrl. Spontaneous activity and average movement speed. Two weeks after weaning, an open field test was conducted to measure spontaneous activity and average movement speed. Ctrl: control group, NMN:NMN group, n=20 for each group, values ​​are mean ± standard error, *: p<0.05 Student's t-test vs Ctrl. Blood triglyceride concentration. Two weeks after weaning, plasma was isolated from blood obtained by whole blood collection, and triglyceride concentration was measured. Ctrl: control group (n=7), NMN:NMN group (n=5), values ​​are mean ± standard error. Blood glucose level. Two weeks after weaning, plasma was isolated from blood obtained by whole blood collection, and blood glucose levels were measured. Ctrl: Control group (n=7), NMN:NMN group (n=5), values ​​are mean ± standard error, **: p<0.01 Student's t-test vs Ctrl. Relative white fat weight. Two weeks after weaning, the rats were dissected and the white fat weight was measured. Ctrl: Control group, NMN:NMN group, n=10 for each group, values ​​are mean ± standard error, **: p<0.01 Student's t-test vs Ctrl.

[0022] [Active ingredient] The composition of the present embodiment contains a precursor of nicotinamide adenine dinucleotide (NAD) as an active ingredient. Note that the active ingredient refers to a component that contributes to a purpose, and in the case of functional food products, it is sometimes referred to as a functional component.

[0023] In the present invention, the term "NAD precursor" refers to NAD itself or a substance that can be converted to NAD in vivo. NAD functions as a coenzyme for various dehydrogenases in vivo and can exist in two forms: oxidized (NAD+) and reduced (NADH). In the present invention, when referring to NAD, it can refer to either oxidized NAD+ or reduced NADH, unless otherwise specified.

[0024] The composition may contain only one type of NAD precursor, or two or more types of NAD precursors.

[0025] In one embodiment, the composition includes, as a precursor of NAD, any of the nicotinamide mononucleotide derivatives, which are compounds represented by the following general formula (I):

[0026]

[0027] In the formula, R 1 and R 2 are each independently an acyl group having 6 to 16 carbon atoms, and the hydrocarbon group bonded to the carbonyl carbon of the acyl group is a linear or branched, saturated or unsaturated hydrocarbon group. Such a compound can be produced by acylation of NMN in a solvent containing 20% ​​by mass or more of a strongly acidic liquid having a pKa of 2.0 or less, using an acylating agent selected from the group consisting of a carboxylic acid having an acyl group having 6 to 16 carbon atoms, in which a linear or branched, saturated or unsaturated hydrocarbon group is bonded to the carbonyl carbon, a halide of the carboxylic acid, and an anhydride of the carboxylic acid (see WO2017 / 110317).

[0028] In one embodiment, the composition comprises, as a precursor of NAD, any one selected from the group consisting of nicotinamide mononucleotide (NMN), nicotinic acid, nicotinamide (also referred to as niacinamide), nicotinamide riboside, reduced nicotinamide riboside, β-trigonelline, nicotinic acid mononucleotide, nicotinic acid riboside, tryptophan, and food- or pharmaceutically acceptable salts thereof.

[0029] In a preferred embodiment, the composition comprises NMN, or a food- or pharmaceutically acceptable salt thereof, as a precursor of NAD.

[0030] NMN exists as two optical isomers, α-type and β-type, but in the present invention, unless otherwise specified, the term NMN refers to β-type NMN (β-nicotinamide mononucleotide). NMN is an intermediate metabolic product of NAD+.

[0031] The term "salts acceptable for use as foods or pharmaceuticals" refers to any salt selected from the group consisting of nitrates, sulfates, carbonates, bicarbonates, halogen salts, formates, acetates, citrates, tartrates, oxalates, fumarates, salts of saturated or unsaturated fatty acids having 3 to 20 carbon atoms, salts of carnitine and its derivatives, salts of hydroxycitric acid and its derivatives, salts of ascorbic acid and its derivatives, salts of ascorbyl phosphate and its derivatives, sodium salts, potassium salts, calcium salts, magnesium salts, zinc salts, and ammonium salts.

[0032] NAD precursors, NMN, nicotinic acid, nicotinamide, nicotinamide riboside, reduced nicotinamide riboside, β-trigonelline, nicotinic acid mononucleotide, nicotinic acid riboside, tryptophan, and food- or pharmaceutically acceptable salts thereof can be produced by various methods, including synthesis, extraction from natural products containing the substances, or cultures of yeast or the like.

[0033] [Uses] The composition of the present embodiment is used for any one selected from the group consisting of improving athletic ability in children, reducing blood triglyceride levels in children, reducing blood sugar levels in children, and suppressing fat accumulation in children. Note that, in the context of the present invention, when referring to any one of these, the number and type of each can be arbitrary.

[0034] In the present invention, the term "child" does not refer to a human child unless otherwise specified. In the present invention, age refers to a human age unless otherwise specified or the context indicates the age of a specific animal. For example, simply referring to 3 years old refers to 3 years old in humans. In the case of a mouse, this refers to approximately 4 weeks of age, which corresponds to 3 years old in humans. The relationship between human and mouse ages can be seen in S. Dutta, P. Sengupta. Life Sciences 152 (2016) 244-248. In the present invention, the term "child" refers to a human under 18 years old, including those before weaning, during weaning, and for a period after weaning (e.g., from weaning to around 3 years of age), as well as toddlers.

[0035] The weaning period refers to the period when a baby takes in nutritional sources other than breast milk or its substitutes along with breast milk or its substitutes. In humans, this period usually lasts from 4-6 months to about 18 months of age, although this varies from person to person. Note that "pre-weaning" refers to the period before and during weaning, while "post-weaning" refers to the period after weaning, not including the weaning period.

[0036] In the present invention, the term "treatment" for a disease or condition includes reducing the risk of onset, delaying onset, preventing, treating, and halting or delaying progression. Treatment includes medical procedures performed by physicians for the purpose of treating a disease, as well as non-medical procedures performed by individuals other than physicians, such as nutritionists, registered dietitians, public health nurses, midwives, nurses, clinical laboratory technicians, food manufacturers, and food retailers. Treatment also includes the administration or recommendation of specific foods, dietary guidance, health guidance, nutritional guidance (including nutritional guidance for the medical treatment of injured or sick individuals and nutritional guidance for maintaining and promoting health), meal management, and guidance necessary for improving nutrition related to meal service. Targets of treatment in the present invention include humans (individuals) and non-human mammals (e.g., companion animals). Furthermore, in the present invention, "ingestion" can be interpreted as "administration." "Administration" can be used not only in reference to pharmaceutical compositions but also in reference to food compositions.

[0037] (Functions and Actions) <Improvement of Motor Ability> In one embodiment, the composition is used to improve the motor ability of children.

[0038] According to the research of the present inventors, mice administered NMN during infancy, more specifically mice administered NMN until the 21st day after birth (the day of weaning), were found to have increased grip strength three weeks after weaning (which, according to the above literature, corresponds to 4.6 years in human years) compared to control mice.

[0039] Therefore, in one embodiment, the composition is used to be administered to children at any stage selected from the group consisting of before weaning, during weaning, and for a period after weaning (e.g., from after weaning to around 3 years of age), and is preferably used to be administered to children before weaning (before weaning and during weaning).

[0040] In another embodiment, the composition is used to improve the motor skills of children after the intake period. For example, the composition is used to improve the motor skills of children at any time selected from the period after weaning, for a period after weaning (e.g., from after weaning to about 3 years of age), or from 3 to 5 years of age. Preferably, the composition is used to improve the motor skills of children after weaning.

[0041] In a particularly preferred embodiment, the composition is taken by a child at a certain stage and used to improve the child's motor skills after that stage. For example, the composition is taken by a child at any stage selected from before weaning, during weaning, and for a period after weaning (for example, from after weaning to around 3 years of age), and used to improve the child's motor skills after weaning, for a period after weaning (for example, from after weaning to around 3 years of age), and for a period after 3 to 5 years of age. Preferably, the composition is taken by a child before weaning and used to improve the child's motor skills after weaning.

[0042] Improvement of motor skills includes promotion of skeletal muscle development and improvement of activity. Promotion of skeletal muscle development can be evaluated by improvement of muscle strength. Activity refers to being active. Improvement of activity can be evaluated, for example, by an increase in the amount of spontaneous activity or an increase in average movement speed. Improvement of activity can also be due to improvement of brain function (central system such as nerves).

[0043] Improvement in motor skills can be evaluated by, for example, standing up, crawling, squatting, walking alone, walking with alternating arms and legs, standing on one leg, climbing stairs, hopping on both feet, hanging on both hands, running, throwing, kicking, etc.

[0044] Improvement in athletic performance can also be assessed by, for example, the 25-meter sprint, standing long jump, ball throw, double jump, body support duration, and ball catching. Improvement in athletic performance can also be assessed by, for example, grip strength, sit-ups, long sit-to-stand bends, repeated side jumps, 20-meter shuttle run, 50-meter sprint, standing long jump, and softball throw.

[0045] In one aspect, the compositions of the present invention are used to maintain athletic performance, or to aid in maintaining or improving athletic performance.

[0046] In one embodiment, the compositions of the present invention are used to treat diseases or conditions related to athletic performance that can be expected to be improved by improving athletic performance.

[0047] Reduction of Blood Triglyceride Levels In one aspect, the composition is used to reduce blood triglyceride levels in children. Blood triglycerides are also known as neutral fats.

[0048] Triglycerides, also known simply as fat, are the lipids found in foods such as meat, fish, and edible oils, and make up the majority of body fat. They are an important source of energy and essential for the intake of fat-soluble vitamins and essential fatty acids. However, excessive intake can lead to obesity and lifestyle-related diseases, resulting in the accumulation of body fat. Generally, blood triglyceride levels of 150 mg / dL or higher are considered hypertriglyceridemia.

[0049] According to the research of the present inventors, mice administered NMN during infancy, more specifically mice administered NMN until the 21st day after birth (the day of weaning), tended to have lower blood triglyceride concentrations two weeks after weaning (which, according to the above literature, corresponds to 3.8 years in human years) compared to control mice.

[0050] Therefore, in one embodiment, the composition is used to be administered to children at any stage selected from the group consisting of before weaning, during weaning, and for a period after weaning (e.g., from after weaning to around 3 years of age), and is preferably used to be administered to children before weaning (before weaning and during weaning).

[0051] In another embodiment, the composition is used to reduce blood triglyceride levels in children after the intake period. For example, the composition is used to reduce blood triglyceride levels in children at any time selected from the weaning period, the period after weaning (e.g., from weaning to about age 3), or the ages of 3 to 5. Preferably, the composition is used to reduce blood triglyceride levels in children after weaning.

[0052] In a particularly preferred embodiment, the composition is ingested by a child at a certain stage and used to reduce the child's blood triglyceride level after that stage. For example, the composition is ingested by a child at any stage selected from before weaning, during weaning, and for a period after weaning (e.g., from after weaning to around 3 years of age), and used to reduce the child's blood triglyceride level after weaning, for a period after weaning (e.g., from after weaning to around 3 years of age), and for a period after 3 to 5 years of age. Preferably, the composition is ingested by a child before weaning and used to reduce the child's blood triglyceride level after weaning.

[0053] Reduction of blood triglyceride levels can be measured, for example, using separated plasma and using commercially available kits.

[0054] In one aspect, the compositions of the present invention are used to maintain blood triglyceride levels and to help maintain good reduced blood triglyceride levels.

[0055] In one aspect, the compositions of the present invention are used for the treatment of diseases or conditions associated with blood triglyceride levels that can be expected to be improved by reducing blood triglyceride levels.

[0056] Reduction of Blood Sugar Levels In one embodiment, the composition is used to reduce blood sugar levels in children.

[0057] Blood glucose level is the concentration of glucose in the blood. Carbohydrates in the diet are digested and absorbed, becoming glucose and entering the bloodstream. Human blood glucose levels are maintained within a relatively narrow range (approximately 70-100 mg / dL when fasting) through the actions of insulin, glucagon, etc. Hyperglycemia occurs when blood glucose levels remain high and do not decrease. If this condition persists for a long time, it can damage blood vessels and lead to arteriosclerosis. Diabetes is a disease in which blood glucose levels are chronically high due to insufficient insulin secretion, or when insulin is secreted but does not work properly. In recent years, the number of children with type 2 diabetes has been increasing, so being able to reduce and maintain low blood glucose levels is expected to play a preventative role in preventing the onset of diabetes.

[0058] According to the research of the present inventors, mice administered NMN during infancy, more specifically mice administered NMN until the 21st day after birth (the day of weaning), had significantly lower blood glucose levels two weeks after weaning (which, according to the above literature, corresponds to 3.8 years in human years) compared to control mice.

[0059] Therefore, in one embodiment, the composition is used to be administered to children at any stage selected from the group consisting of before weaning, during weaning, and for a period after weaning (e.g., from after weaning to around 3 years of age), and is preferably used to be administered to children before weaning (before weaning and during weaning).

[0060] In another aspect, the composition is used to reduce blood glucose levels in children after the intake period. For example, the composition is used to reduce blood glucose levels in children at any time selected from the period after weaning, for a period after weaning (e.g., from weaning to about age 3), or ages 3 to 5. Preferably, the composition is used to reduce blood glucose levels in children after weaning.

[0061] In a particularly preferred embodiment, the composition is administered to a child at a certain stage and used to reduce the child's blood glucose level after that stage. For example, the composition is administered to a child at any stage selected from before weaning, during weaning, and for a period after weaning (e.g., from after weaning to around 3 years of age), and used to reduce the child's blood glucose level after weaning, for a period after weaning (e.g., from after weaning to around 3 years of age), and for a period after 3 to 5 years of age. Preferably, the composition is administered to a child before weaning and used to reduce the child's blood glucose level after weaning.

[0062] The reduction in blood glucose levels can be measured, for example, using separated plasma and commercially available kits.

[0063] In one aspect, the compositions of the present invention are used to maintain blood glucose levels, to help maintain good blood glucose reduction.

[0064] In one embodiment, the compositions of the present invention are used for the treatment of blood glucose-related diseases or conditions that can be expected to improve by reducing blood glucose levels.

[0065] Inhibition of Fat Accumulation In one embodiment, the composition is used to inhibit fat accumulation in children.

[0066] Generally, when referring to body fat, it includes visceral fat and subcutaneous fat. According to the study by the present inventors, mice administered NMN in infancy had lower white fat around the reproductive organs after weaning compared to control mice, so the composition of the present invention is suitable for suppressing the accumulation of fat, especially visceral fat.

[0067] According to the research of the present inventors, mice administered NMN during infancy, more specifically mice administered NMN until the 21st day after birth (the day of weaning), tended to have lower fat accumulation concentrations two weeks after weaning (which, according to the above literature, corresponds to 3.8 years in human years) compared to control mice.

[0068] Therefore, in one embodiment, the composition is used to be administered to children at any stage selected from the group consisting of before weaning, during weaning, and for a period after weaning (e.g., from after weaning to around 3 years of age), and is preferably used to be administered to children before weaning (before weaning and during weaning).

[0069] In another embodiment, the composition is used to suppress fat accumulation in children after the intake period. For example, the composition is used to suppress fat accumulation in children at any time selected from after weaning, for a period after weaning (e.g., from after weaning to about age 3), or from age 3 to age 5. Preferably, the composition is used to suppress fat accumulation in children after weaning.

[0070] In a particularly preferred embodiment, the composition is administered to a child at a certain stage and used to suppress fat accumulation in the child after that stage. For example, the composition is administered to a child at any stage selected from before weaning, during weaning, and for a period after weaning (for example, from after weaning to around 3 years of age), and used to suppress fat accumulation in the child after weaning, for a period after weaning (for example, from after weaning to around 3 years of age), and for a period between 3 and 5 years of age. Preferably, the composition is administered to a child before weaning and used to suppress fat accumulation in the child after weaning.

[0071] The amount or degree of body fat accumulation can be measured, for example, using a CT scanner or a body fat scale (electrical conductivity method or bioelectrical impedance method). It can also be estimated by measuring abdominal circumference, which is said to be roughly proportional to the accumulation of visceral fat.

[0072] In one embodiment, the compositions of the present invention are used to prevent fat accumulation and to help maintain a well-controlled state of fat accumulation.

[0073] In one embodiment, the compositions of the present invention are used for the treatment of diseases or conditions associated with fat accumulation that can be expected to be improved by inhibiting fat accumulation.

[0074] (Target) The composition of this embodiment is intended for consumption by children (under 18 years of age). In relation to the present invention, unless otherwise specified, the term "children" includes infants (under 1 year of age, including newborns up to 1 month of age), toddlers (1 year or older but under 6 years of age), and juveniles (6 years or older but under 18 years of age).

[0075] The composition of one embodiment is suitable for administration to a subject desiring or in need of improved athletic performance. The composition of one embodiment is also expected to be applicable to the treatment of diseases or conditions related to athletic performance in children. The composition of one embodiment is suitable for administration to a subject desiring or in need of reduced blood triglyceride levels. The composition of one embodiment is also expected to be applicable to the treatment of diseases or conditions related to blood triglyceride levels in children. The composition of one embodiment is suitable for administration to a subject desiring or in need of reduced blood glucose levels. The composition of one embodiment is also expected to be applicable to the treatment of diseases or conditions related to blood glucose levels in children. The composition of one embodiment is suitable for administration to a subject desiring or in need of suppression of fat accumulation. The composition of one embodiment is also expected to be applicable to the treatment of diseases or conditions related to fat accumulation in children.

[0076] In one embodiment, the composition is used for feeding to infants or young children before weaning. In another embodiment, the composition of the present invention is used for any of the following purposes in infants or young children: improving athletic performance, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation. In a particularly preferred embodiment, the composition of the present invention is fed to infants or young children before weaning and for any of the following purposes in the child: improving athletic performance, reducing blood triglycerides, reducing blood glucose levels, and suppressing fat accumulation.

[0077] In one aspect, the composition is suitable for administration to a subject who desires or requires formula feeding rather than breastfeeding. The composition is also suitable for administration to non-human animals.

[0078] [Composition] (Dosage form / shape) The composition of this embodiment can be prepared in any form, such as a solid, liquid, mixture, suspension, emulsion, gel, or sol. The composition of this embodiment can be an artificial (synthesized) nutritional composition prepared by mixing various ingredients. An artificial nutritional composition may also be simply referred to as a nutritional composition. Nutritional compositions do not include biosynthesized compositions, such as breast milk. In the present invention, when a composition (including a nutritional composition) is referred to as being for children, it refers to a composition intended for consumption by children, and does not include a composition intended for consumption by pregnant women or nursing mothers.

[0079] In a particularly preferred embodiment, the composition is in the form of an infant formula, a liquid formula, or a breast milk substitute. Powdered formula refers to a powdered product obtained by processing raw milk, cow's milk, special cow's milk, or a food product made from these ingredients, or using these as the main ingredient, and adding nutrients necessary for infants to the processed product. Liquid formula refers to a liquid product obtained by processing raw milk, cow's milk, special cow's milk, or a food product made from these ingredients, or using these as the main ingredient, and adding nutrients necessary for infants to the processed product.

[0080] Formulated powdered milk, formula liquid milk, or breast milk substitutes can be for infants, follow-up, low birth weight infants, children, adults, the elderly, allergies, lactose intolerance, or congenital metabolic disorders. In Japan, follow-up refers to products that provide a balanced intake of nutrients necessary for infants and toddlers from the weaning period around 9 months of age until around 3 years of age.

[0081] In one embodiment, the prepared powdered milk is used after being dissolved to a concentration of 5 to 17%, preferably 8 to 16%, more preferably 12 to 15%. The prepared powdered milk can be packaged in a stick or rectangular shape for a single serving (e.g., the amount required to prepare 200 ml of milk by dissolving in hot water).

[0082] The composition of this embodiment may be a food or pharmaceutical composition other than infant formula, liquid infant formula, or breast milk substitute. Foods and pharmaceuticals include not only those for humans but also those for non-human animals, unless otherwise specified. Foods include general foods, functional foods, infant foods, and nutritional compositions, as well as therapeutic foods (those that serve therapeutic purposes; prepared based on a menu created by a nutritionist or other professional prescribed by a doctor), dietary therapy foods, ingredient-modified foods, nursing care foods, and therapeutic support foods, unless otherwise specified. Foods include not only solid foods but also liquid foods, such as beverages, energy drinks, liquid foods, and soups, unless otherwise specified. Functional foods refer to foods that can impart specific functionality to the body, and include a wide range of health foods, including foods for specified health uses (including conditional FOSHUs [foods for specified health uses]), foods with functional claims, health functional foods including foods with nutrient functions, foods for special dietary uses, dietary supplements, health supplements, supplements (e.g., tablets, coated tablets, sugar-coated tablets, capsules, liquids, etc.), and beauty foods (e.g., diet foods). Furthermore, in the context of the present invention, functional foods include health foods to which a health claim based on the Codex Alimentarius (the Joint FAO / WHO Food Standards Commission) is applied. Cosmetics include medicated cosmetics.

[0083] When the composition of the embodiment is a food product, it can be in any form, such as a supplement, confectionery, beverage, drink, seasoning, dairy product, processed food, prepared dish, soup, etc. Specifically, the composition of the present invention can be in the form of gummies, tablets, drink, fermented milk, dairy drink, milk-based drink, soft drink, ice cream, cheese, bread, biscuits, crackers, pizza crust, infant formula, liquid food, food for the sick, nutritional food, frozen food, processed food, etc. It can also be in the form of granules, powder, paste, thick liquid, etc., for mixing with beverages or foods or for diluting to prepare beverages, etc., specifically, it can be in the form of a syrup for adding to milk.

[0084] When the composition of the present embodiment is a pharmaceutical product, specific examples of the form include chewable tablets, sublingual tablets, tablets, pills, capsules, granules, powders, liquids, suspensions, emulsions, syrups, liniments, lotions, gels, aerosols, sprays, ointments, creams, tapes, poultices, eye drops, nasal drops, and suppositories.

[0085] (Content and Dosage of Active Ingredient) The content and concentration of the NAD precursor in the composition of this embodiment (when multiple types of NAD precursors are used, the total content and concentration) may be any amount that achieves the desired effect and can be appropriately set taking into consideration various factors such as the subject's age, body weight, and the desired effect. In relation to the present invention, when the amount or concentration of the NAD precursor in the composition is indicated, the amount or concentration is that of NMN, unless otherwise specified. When an NAD precursor other than NMN is used as the active ingredient, an NAD precursor in an equimolar amount or concentration to that amount or concentration of NMN can be used. This conversion can be easily performed by those skilled in the art. The following description of the amount or concentration will be given using NMN as an example of the NAD precursor, but those skilled in the art can also apply this description to cases where an NAD precursor other than NMN is used.

[0086] When the composition of this embodiment is solid, such as a powdered milk, the amount of NMN per 100 g of the composition can be 0.05 mg or more, preferably 0.1 mg or more, more preferably 0.5 mg or more, and even more preferably 1 mg or more. The amount of NMN per 100 g of the composition can be 1.1 mg or more, 1.5 mg or more, 2 mg or more, 2.5 mg or more, 3 mg or more, 4 mg or more, 4.5 mg or more, 5 mg or more, 6 mg or more, 7 mg or more, 8 mg or more, 9 mg or more, or 10 mg or more.

[0087] When the composition of this embodiment is solid, for example, in the form of infant formula, the upper limit of the amount of NMN per 100 g of the composition can be 200 mg or less, or alternatively 100 mg or less, 50 mg or less, or 10 mg or less. From the viewpoint of being within the range of the amount normally contained in breast milk, the amount of NMN per 100 g of the composition can be 16.1 mg or less, or alternatively 13 mg or less.

[0088] When the composition of this embodiment is liquid, for example, a liquid milk preparation, the NMN concentration of the composition can be 0.025 μg / mL or more, preferably 0.05 μg / mL or more, more preferably 0.25 μg / mL or more, even more preferably 0.5 μg / mL or more, even more preferably 0.85 μg / mL or more, and even more preferably 1.7 μg / mL or more, or 1.8 μg / mL or more, or 2 μg / mL or more, or 2.2 μg / mL or more, or 2.4 μg / mL or more, or 2.6 μg / mL or more, or 3 μg / mL or more, or 3.5 μg / mL or more, or 3.7 μg / mL or more, or 4 μg / mL or more, or 4.3 μg / mL or more, or 4.6 μg / mL or more, or 5 μg / mL or more, or even 5.5 μg / mL or more.

[0089] When the composition of this embodiment is liquid, for example, a liquid formula, the upper limit of the NMN concentration of the composition can be 340 μg / mL or less, or alternatively 170 μg / mL or less, 85 μg / mL or less, 25 μg / mL or less, 17 μg / mL or less, or even 5 μg / mL or less. From the viewpoint of being within the range of the amount normally contained in breast milk, the NMN concentration is preferably 8.1 μg / mL or less, or alternatively 6.0 μg / mL or less, or alternatively 3.1 μg / mL or less.

[0090] The content of NMN in the composition of this embodiment may be designed taking into account the amount of NMN per day. The daily amount of NMN can be 0.013 mg or more, preferably 0.25 mg or more, more preferably 0.43 mg or more, and even more preferably 0.85 mg or more. The daily amount of NMN may also be 0.9 mg or more, 1 mg or more, 1.2 mg or more, 1.6 mg or more, 2 mg or more, 3 mg or more, 6 mg or more, 6.3 mg or more, 6.6 mg or more, 7 mg or more, 7.5 mg or more, or 8 mg or more.

[0091] The upper limit of the daily dose of NMN can be 170 mg or less, or may be 85 mg or less, 43 mg or less, 13 mg or less, 8.5 mg or less, or 2.5 mg or less. From the viewpoint of being within the range of the amount normally contained in breast milk, the daily dose of NMN is preferably 8.1 mg or less, and may be 6.0 mg or less.

[0092] Such daily dose may be divided into multiple portions, for example 3 to 7 portions, suitable for consumption 3 to 7 times daily.

[0093] The composition of the present embodiment may be taken at any time of day. When the composition of the present embodiment is in the form of an infant formula, a liquid infant formula, or a breast milk substitute, the composition of the present embodiment can be used to feed a baby in the same manner as breastfeeding.

[0094] It is believed that NAD concentrations in the body vary throughout the day and increase during periods of activity. From this perspective, in one embodiment, it is believed that it is preferable to ingest more of the composition in the morning, which corresponds to the start of the active period.

[0095] (Other Ingredients, Additives) In addition to the NAD precursor, the composition of this embodiment may contain other nutritional ingredients that are acceptable as foods or pharmaceuticals. For example, when the composition is in the form of infant formula, infant formula, or breast milk substitute, ingredients other than NMN may include protein, lipids, cholesterol, carbohydrates, niacin, pantothenic acid, biotin, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, folic acid, zinc, sodium, potassium, calcium, selenium, iron, copper, magnesium, phosphorus, lactadherin, α-lactalbumin, β-lactoglobulin, arachidonic acid (ARA), docosahexaenoic acid (DHA), linoleic acid, α-linolenic acid, phospholipids, fructooligosaccharides, inositol, β-carotene, chlorine, carnitine, taurine, nucleotides, etc.

[0096] The composition of the present invention may also contain, in addition to the NAD precursor, other active ingredients or nutritional ingredients that are acceptable as foods or pharmaceuticals.

[0097] The composition of the present embodiment may further contain additives acceptable for use as foods or pharmaceuticals, such as inert carriers (solid or liquid carriers), excipients, surfactants, binders, disintegrants, lubricants, solubilizers, suspending agents, coating agents, colorants, preservatives, buffers, pH adjusters, emulsifiers, stabilizers, sweeteners, antioxidants, flavors, acidulants, and natural products.

[0098] (Method of Use) The composition of this embodiment is used orally. It may also be administered parenterally, for example, via a tube (such as a gastrostomy or enterostomy) or nasally, but is preferably used orally.

[0099] The composition of this embodiment can be repeatedly ingested by a subject, and can be continuously ingested by a subject for a long period of time. The period is not particularly limited, but in order to fully observe the effect, it is preferable to continuously ingest it for a relatively long period of time, for example, 1 week or more, 2 weeks or more, 1 month or more, 3 months or more, 6 months or more, or 1 year or more. Since the active ingredient NMN is a substance that has a long history of consumption and is originally contained in breast milk, the composition of this embodiment is particularly suitable for long-term ingestion.

[0100] (Other) The composition of the present embodiment is used in combination with the ingestion of other ingredients, the ingestion of health foods and supplements, exercise, a normal diet, etc. The composition of the present embodiment may also be used in combination with any of a therapy selected from a therapy that promotes the improvement of athletic performance, a therapy that promotes the reduction of blood triglycerides, a therapy that promotes the reduction of blood glucose levels, and a therapy that promotes the suppression of fat accumulation.

[0101] The composition of this embodiment can be appropriately produced by a person skilled in the art using existing equipment, etc. In producing the composition of this embodiment, the stage of blending NMN is not particularly limited as long as it does not significantly impair the properties of NMN.

[0102] The composition of this embodiment can be produced according to conventional methods, even in the form of infant formula, liquid formula, or breast milk substitute. For example, infant formula can be produced as follows: processed whey protein, casein, processed soy protein, sugars (lactose, oligosaccharides), minerals, vitamins, and oils (including fatty acids such as ARA, DHA, linoleic acid, and α-linolenic acid) are blended, dissolved, mixed, and purified, followed by sterilization, concentration, homogenization, and spray drying or other drying processes to obtain infant formula. Again, the stage of blending NMN is not particularly limited, as long as it does not significantly impair the properties of NMN.

[0103] Products containing the composition of this embodiment can be labeled with their functions and intended uses (applications), and can also be labeled with recommendations for administration or ingestion to specific subjects. Labeling can be direct or indirect. Examples of direct labeling include descriptions on tangible objects such as the product itself, packaging, containers, labels, and tags. Examples of indirect labeling include advertising and promotional activities via locations or means such as websites, stores, pamphlets, exhibitions, media seminars, books, newspapers, magazines, television, radio, mail, email, and audio. Examples of labeled functions and intended uses (applications) include "helps improve athletic performance," "helps maintain athletic performance," "helps reduce blood triglyceride levels," "helps maintain low blood triglyceride levels," "helps reduce blood glucose levels," "helps maintain low blood glucose levels," "helps inhibit fat accumulation," "for babies up to 6 months of age," "for infants," "for young children," etc.

[0104] We examined whether administering NMN to infant mice would affect the development of motor skills, blood triglyceride levels, blood glucose levels, and white fat accumulation (lipid metabolism) after weaning.

[0105] [Common Methods for Examples 1 to 4] 1) Administration Material β-Nicotinamide Mononucleotide (NMN) to be administered to mice was dissolved in distilled water at a concentration of 100 mg / mL and then used for administration.

[0106] 2) Animals: Ten female C57BL / 6J mice on day 13 of pregnancy were purchased. The mice were housed individually in a breeding room with a room temperature of 22±2°C, humidity of 55±15%, and a light cycle of 7:00 AM to 7:00 PM and a dark cycle of 7:00 PM to 7:00 AM until the birth of pups. After the birth, the mice were housed in groups with the pups until weaning, and the newborn mice were used in the study.

[0107] 3) NMN administration All pups were sexed on day 3 after birth and divided into two groups: one receiving distilled water (the later control group) and the other receiving NMN (the later NMN group) so that approximately half of the litter was male and half female. For the NMN-administered mice, an NMN solution was administered orally by force at a dose of 10 μL / body per day from day 3 to day 13 after birth, and at a dose of 5 mL / kg BW (500 mg / kg BW) from day 14 to day 21 (weaning day). For the distilled water-administered mice, distilled water was administered orally by force at the same dose and frequency.

[0108] [Example 1: Effect on the development of motor skills after weaning] (Method) 1) Grouping All pups were weighed on the day of weaning, and divided into four groups (n = 10 per group): a control group and an NMN group for males, and a control group and an NMN group for females, so that the average weights were equal. After weaning, the mice were kept in the usual conditions until the day of measurement of grip strength, spontaneous activity, and average movement speed.

[0109] 2) Measurement of Grip Strength Three weeks after weaning, the grip strength (forelimbs only) of all mice was measured using a mouse / rat grip strength measuring device (MK-380CM / F, Muromachi Kikai Co., Ltd.). Measurements were performed 10 times per mouse, and the highest value was recorded. Grip strength values ​​were calculated by correcting for the body weight of each mouse.

[0110] 3) Measurement of spontaneous activity and average movement speed Two weeks after weaning, all mice underwent an open field test to measure spontaneous activity and average movement speed. Mice were placed in an open field tank (Shin Factory) and videotaped while they moved freely for 10 minutes. Spontaneous activity (total distance moved) and average movement speed (average movement speed excluding immobile periods) were calculated from the video using dedicated analysis software (SMART3.0: ​​Panlab).

[0111] (Results) 1) Grip strength Compared to the control group, the NMN group had higher grip strength when comparing both males and females (Figure 1-1).

[0112] 2) Spontaneous activity and average movement speed: Compared to the control group, the NMN group had higher spontaneous activity and average movement speed when comparing both males and females (Figure 1-2).

[0113] (Discussion) Administration of NMN during infancy increased grip strength, spontaneous activity, and average movement speed after weaning. It has been reported that mice with high brain expression of SIRT1 (Feldman JL, Dittenhafer-Reed KE, Denu JM. J Biol Chem. 2012; 287:42419-42427), which functions as a coenzyme for NAD+, exhibit improved skeletal muscle function and increased spontaneous activity (Non-Patent Document 1, cited above), and that clinical trials involving NMN intervention have shown improved motor skills (Non-Patent Document 2, cited above). Therefore, in this study, administration of NMN during infancy increased NAD+ levels in the brain and skeletal muscle, promoting skeletal muscle growth and development, possibly resulting in improved motor skills through increased muscle strength.

[0114] (Conclusion) We have demonstrated that administering NMN during infancy improves motor skills such as grip strength, spontaneous activity, and average movement speed after weaning. This invention will lead to elucidation of the physiological significance of NMN contained in breast milk, and will be useful for the healthy growth and development of many children.

[0115] [Example 2: Effect on blood triglyceride levels after weaning] (Method) 1) Grouping On the day of weaning, the weight of the pups was measured and they were divided into two groups: a male-only control group (n = 7) and an NMN group (n = 5). After weaning, the mice were raised normally for two weeks, and plasma was separated from the blood obtained by whole blood collection.

[0116] 2) Measurement of triglyceride concentration Using the separated plasma, the triglyceride concentration was measured using a kit (Triglyceride E Test Wako: No. 432-40201).

[0117] (Results) Blood triglyceride levels: Compared to the control group, the NMN group showed a tendency for blood triglyceride levels to be lower (Figure 2).

[0118] (Discussion) Administration of NMN during infancy reduced blood triglyceride levels after weaning. It has already been reported that administering NMN to mice after feeding them a high-fat diet improved lipid metabolism and reduced triglyceride levels in the liver (Non-Patent Document 3, cited above). Therefore, this study suggests that administering NMN during infancy may have affected lipid metabolism, resulting in a decrease in blood triglyceride levels. (Conclusion) This study demonstrated that administering NMN during infancy reduces blood triglyceride levels after weaning. This invention will help elucidate the physiological significance of NMN contained in breast milk and will be useful for the healthy growth and development of many children.

[0119] [Example 3: Effect on blood glucose levels after weaning] (Method) 1) Grouping The weight of the pups was measured on the day of weaning, and they were divided into two groups: a male-only control group (n = 7) and an NMN group (n = 5). After weaning, the mice were raised normally for two weeks, and plasma was separated from the blood obtained by whole blood collection.

[0120] 2) Measurement of blood glucose level Using the separated plasma, blood glucose concentration (blood glucose level) was measured using a kit (Glucose II-Test Wako: No. 439-90901).

[0121] (Results) Blood glucose levels Blood glucose levels were significantly lower in the NMN group compared to the control group (Figure 3).

[0122] (Discussion) Administration of NMN during infancy resulted in low blood glucose levels after weaning. It has already been reported that in a study in which mice were given NMN after being fed a high-fat diet, glucose tolerance improved and the production of incretin (GLP-1) in the gastrointestinal tissue increased (Non-Patent Documents 3, 4). Therefore, it is possible that administration of NMN during infancy in this study reduced blood glucose levels by affecting glucose tolerance (sugar metabolism).

[0123] (Conclusion) This study demonstrated that administering NMN during infancy reduces blood glucose levels after weaning. This study will help elucidate the physiological significance of NMN contained in breast milk and will be useful for the healthy growth and development of many children.

[0124] Example 4: Effect on white fat accumulation (lipid metabolism) after weaning (Method) Grouping and white fat weight measurement On the day of weaning, all pups were weighed and divided into four groups: a control group (n=7) and an NMN group (n=5) for males, and a control group (n=3) and an NMN group (n=5) for females. After weaning, the mice were kept under normal conditions for two weeks, dissected, and the white adipose tissue around the reproductive organs was extracted and weighed. The white fat weight was corrected for the body weight of each individual to calculate the relative weight.

[0125] (Results) White fat weight Compared to the control group, the NMN group had lower white fat weight in both males and females (Figure 4).

[0126] (Discussion) Administration of NMN during infancy suppressed white fat weight after weaning. It has already been reported that in studies in which mice were given NMN after being fed a high-fat diet, glucose tolerance and lipid metabolism improved, and the production of incretin (GLP-1) in gastrointestinal tissue increased (Non-Patent Documents 3 and 4 cited above). Therefore, it is possible that administration of NMN during infancy in this study affected glucose tolerance and lipid metabolism, suppressing the accumulation of white fat.

[0127] (Conclusion) We have demonstrated that administering NMN during infancy suppresses the accumulation of white fat after weaning. This invention will help elucidate the physiological significance of NMN contained in breast milk and will be useful for the healthy growth and development of many children.

[0128] [Example of manufacturing modified powdered milk] NMN is added to the raw materials so that the concentration in the final product (in the case of modified powdered milk that is dissolved to a concentration of 5 to 17% (w / v)) is 0.1 to 100 mg / 100 g, for example 16.2 to 100 mg / 100 g, and the mixture is dissolved, mixed, and purified according to standard methods, followed by sterilization, concentration, homogenization, and spray drying to obtain modified powdered milk.

[0129] According to the present invention, it is possible to provide a pharmaceutical or food composition and a method for producing a pharmaceutical or food that can improve children's athletic ability in the future. According to the present invention, it is possible to provide a pharmaceutical or food composition and a method for producing a pharmaceutical or food that can reduce children's blood triglyceride levels in the future. According to the present invention, it is possible to provide a pharmaceutical or food composition and a method for producing a pharmaceutical or food that can reduce children's blood glucose levels in the future. According to the present invention, it is possible to provide a pharmaceutical or food composition and a method for producing a pharmaceutical or food that can suppress fat accumulation in children in the future. Furthermore, it is expected that the present invention will improve the nutrition of many children, ensure healthy lives, and promote welfare.

Claims

1. A nutritional composition for children, comprising a precursor of nicotinamide adenine dinucleotide (NAD), for promoting child development in any one of the areas selected from improving athletic performance, reducing blood triglycerides, reducing blood sugar levels, and inhibiting fat accumulation.

2. The composition according to claim 1, which is a composition for improving athletic ability, and the improvement in athletic ability is any one selected from the group consisting of promoting the development of skeletal muscles and improving activity.

3. The composition according to claim 1, which is a composition for improving athletic ability, and the improvement in athletic ability is measured by any one selected from the group consisting of an improvement in muscle strength, an increase in spontaneous activity, and an increase in movement speed.

4. The composition according to claim 1, wherein the promotion of child development is the promotion of post-weaning child development.

5. The composition according to claim 1, wherein the promotion of child development is the promotion of child development after the age of 3.

6. A composition according to any one of claims 1 to 5 for ingestion by an infant or a young child.

7. A composition according to any one of claims 1 to 5, intended for consumption by pre-weaning children.

8. The composition according to any one of claims 1 to 5, which is in any form selected from the group consisting of infant formula, infant liquid formula, and breast milk substitute food.

9. A composition described in any one of claims 1 to 5, wherein the precursor of NAD is nicotinamide mononucleotide (NMN).

10. The composition of claim 9, wherein the concentration of NMN when ingested is 0.05 μg / mL or more.

11. The composition of claim 9, which is in the form of an infant formula and contains 0.1 mg or more of NMN per 100 g.

12. A composition for feeding to a pre-weaning child to promote development of the child after weaning, the composition comprising a precursor of nicotinamide adenine dinucleotide (NAD).

13. The composition according to claim 12, wherein the promotion of child development is any one selected from the group consisting of improved athletic ability, reduced blood triglycerides, reduced blood sugar levels, and inhibited fat accumulation.

Citation Information

Patent Citations

  • Adiponectin secretion enhancer

    JP2018131418A

  • Diabetes improving agent or preventive agent

    JP2018203691A

  • Chemotherapy and Radiation Therapy Targeting nad + for the treatment of induced cognitive dysfunction, neuropathy and inactivity

    JP2018514548A

  • Use of NAD precursors to improve maternal and / or child health

    JP2020504168A

  • Methods for increasing vascular density

    JP2020504722A